公开(公告)号：US12109195B2

公开(公告)日：2024-10-08

申请号：US17363193

申请日：2021-06-30

申请人： Vireo Systems, Inc.

发明人： Mark C. Faulkner ,  Deeannah Seymour

IPC分类号： A61K31/41 ,  A61K9/00 ,  A61K9/02 ,  A61K31/194 ,  A61K31/4168 ,  A61K31/7016 ,  A61K31/702 ,  A61K31/733 ,  A61K33/22 ,  A61K35/747 ,  A61P31/04

CPC分类号： A61K31/4168 ,  A61K9/0036 ,  A61K9/02 ,  A61K31/194 ,  A61K31/7016 ,  A61K31/702 ,  A61K31/733 ,  A61K33/22 ,  A61K35/747 ,  A61P31/04

摘要： Compositions and methods for treatment and prevention of vaginal infections where the compositions include creatinine, such as protonated creatinine or creatinine salts, and optionally one or more weak acids, such as boric acid. The compositions may be used to treat and/or prevent a vaginal infection, such as bacterial vaginosis, to prevent recurrence of a vaginal infection, to treat and/or prevent a sexually transmitted disease (STD) or sexually transmitted infection (STI), and reduce the incidence and/or risk of a subject transmitting a STI or STD.

公开(公告)号：US20240261310A1

公开(公告)日：2024-08-08

申请号：US18560456

申请日：2021-05-14

申请人： HAITANG (JIANGSU) BIOTECHNOLOGY COMPANY, LTD.

发明人： Zhende Liu ,  Heyong Gao

IPC分类号： A61K31/702 ,  A61K31/7016 ,  A61P13/12

CPC分类号： A61K31/702 ,  A61K31/7016 ,  A61P13/12

摘要： The present invention provides an alginate oligosaccharide or a pharmaceutically acceptable salt thereof in preparation of a drug for treatment of acute kidney injury, wherein the alginate oligosaccharide is an alginate disaccharide, an alginate trisaccharide, or an alginate tetrasaccharide. Studies have found that the alginate disaccharide, the alginate trisaccharide, and the alginate tetrasaccharide all show significant protective effects on animal models of acute kidney injury induced by ischemia-reperfusion (I/R), endotoxin phosphorus lipopolysaccharides (LPS) and anti-tumor drug cisplatin. After the treatment of acute kidney injury animals by the alginate oligosaccharide of the present invention, the level of serum creatinine decreases significantly, the urine concentration ability of kidneys recovers significantly, the level of renal tubular injury markers (KIM-1 and NGAL) is significantly reduced, the protein expression of inflammatory factors is significantly reduced, the pathological changes of the kidneys are significantly ameliorated, and the therapeutic effect is enhanced with the increase of dose. Therefore, the alginate oligosaccharide of the present invention has a strong effect in the treatment of acute kidney injury.

公开(公告)号：US12016334B2

公开(公告)日：2024-06-25

申请号：US16955326

申请日：2019-11-08

申请人： SEA6ENERGY PVT. LTD.

发明人： Girish Tavarekere Rudrappa ,  Hemanth Giri Rao Vantharam Venkata ,  Pooja Malhotra ,  Sumit Purushottam Bhose ,  Narendrakumar Sekar ,  Sam Kuruvilla ,  Lekshmi Girija ,  Sachin Khandelwal ,  Nithin Sanghe ,  Sawan Kumar ,  Sri Sailaja Nori ,  Shrikumar Suryanarayan

IPC分类号： A01N41/02 ,  A01N43/16 ,  A61K9/00 ,  A61K31/195 ,  A61K31/60 ,  A61K31/7004 ,  A61K31/7016 ,  A61K31/702 ,  A61K33/22 ,  A61K33/30 ,  A61K36/04 ,  A61P31/00

CPC分类号： A01N41/02 ,  A01N43/16 ,  A61K9/0056 ,  A61K31/195 ,  A61K31/60 ,  A61K31/7004 ,  A61K31/7016 ,  A61K31/702 ,  A61K33/22 ,  A61K33/30 ,  A61K36/04 ,  A61P31/00

摘要： The present disclosure discloses a composition comprising: (a) at least one sulphated galactose; and (b) at least one saccharide selected from a group consisting of disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, and salts thereof. The present disclosure further discloses a weight percentage of the at least one sulphated galactose to be in a range of 15-90% with respect to the total sugar content. Further, the present disclosure discloses a use of the composition for protecting/treating plants from infection. Also provided is a use of the composition for protecting/treating animals from infection. The present disclosure discloses a use of sulphated galactose for protecting/treating plants from infection. Also provided is a use of sulphated galactose for protecting/treating animals from infection. The present disclosure also discloses a method for preparing the composition as described herein.

公开(公告)号：US11850303B2

公开(公告)日：2023-12-26

申请号：US16949376

申请日：2020-10-27

申请人： Uqora, Inc.

发明人： Spencer Gordon

IPC分类号： A61K9/06 ,  A61K9/02 ,  A61K31/191 ,  A61K31/7016 ,  A61K31/702 ,  A61K33/40 ,  A61K35/747

CPC分类号： A61K9/06 ,  A61K9/02 ,  A61K31/191 ,  A61K31/702 ,  A61K31/7016 ,  A61K33/40 ,  A61K35/747

摘要： A gel and suppository and method to provide the gel and the suppository, are disclosed herein. The gel comprising: between 50 and 150 millimolar of lactic acid concentrate; and between 0.5 and 10 millimolar of hydrogen peroxide concentrate. The suppository comprising: between 22.5 and 67.5 milligrams of lactic acid concentrate; and between 1 and 20 milligrams of hydrogen peroxide concentrate.

公开(公告)号：US20230330071A1

公开(公告)日：2023-10-19

申请号：US18135823

申请日：2023-04-18

申请人： Salix Pharmaceuticals, Ltd.

发明人： William Forbes

IPC分类号： A61K31/437 ,  A61K31/08 ,  A61K31/352 ,  A61K31/395 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/606 ,  A61K31/7016 ,  A61K31/785 ,  A61K38/14 ,  A61K38/31 ,  A61K45/06

CPC分类号： A61K31/437 ,  A61K31/08 ,  A61K31/352 ,  A61K31/395 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/606 ,  A61K31/7016 ,  A61K31/785 ,  A61K38/14 ,  A61K38/31 ,  A61K45/06

摘要： The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

公开(公告)号：US11690812B2

公开(公告)日：2023-07-04

申请号：US17190018

申请日：2021-03-02

申请人： Duke University ,  National University of Singapore

发明人： Dwight D. Koeberl ,  Paul M. Yen ,  Benjamin L. Farah

IPC分类号： A61K31/137 ,  A61K31/436 ,  A61K31/05 ,  A61K31/155 ,  A61K31/192 ,  A61K38/47 ,  A61K31/522 ,  A61K38/46 ,  A61K31/198 ,  A61K31/12 ,  A61K31/216 ,  A61K31/352 ,  A61K31/167 ,  A61P3/00 ,  A61K31/277 ,  A61K31/355 ,  A61K31/385 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/575 ,  A61K31/7016 ,  A61K33/00

CPC分类号： A61K31/137 ,  A61K31/05 ,  A61K31/12 ,  A61K31/155 ,  A61K31/167 ,  A61K31/192 ,  A61K31/198 ,  A61K31/216 ,  A61K31/277 ,  A61K31/352 ,  A61K31/355 ,  A61K31/385 ,  A61K31/436 ,  A61K31/522 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/575 ,  A61K31/7016 ,  A61K33/00 ,  A61K38/465 ,  A61K38/47 ,  A61P3/00 ,  C12Y301/04012 ,  C12Y302/0102 ,  C12Y302/01022 ,  C12Y302/01045 ,  C12Y302/01049 ,  C12Y302/01076 ,  A61K38/465 ,  A61K2300/00 ,  A61K38/47 ,  A61K2300/00

摘要： The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.

公开(公告)号：US20230201228A1

公开(公告)日：2023-06-29

申请号：US18111103

申请日：2023-02-17

申请人： The Regents of the University of California

发明人： Lars Bode ,  Philip Gordts

IPC分类号： A61K31/702 ,  A61P17/00 ,  A61P29/00 ,  A61K31/7016

CPC分类号： A61K31/702 ,  A61P17/00 ,  A61P29/00 ,  A61K31/7016

摘要： The disclosure provides for immunomodulatory oligosaccharides, and uses thereof.

公开(公告)号：US11672834B2

公开(公告)日：2023-06-13

申请号：US17214562

申请日：2021-03-26

申请人： Evelo Biosciences, Inc.

发明人： David Berry ,  Noubar B. Afeyan ,  Johanne Kaplan ,  Shaila Rahman

IPC分类号： A61K35/74 ,  A61K35/741 ,  A61K35/742 ,  A61K31/7004 ,  A61K35/744 ,  A61K31/715 ,  A61K38/46 ,  A61K35/39 ,  A61P29/00 ,  A61P37/00 ,  A61P43/00 ,  A61K9/00 ,  A61K35/745 ,  A61K35/747 ,  A61K9/19 ,  A61K31/7016 ,  A61K35/00

CPC分类号： A61K35/74 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/19 ,  A61K31/7004 ,  A61K31/7016 ,  A61K31/715 ,  A61K35/39 ,  A61K35/741 ,  A61K35/742 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K38/46 ,  A61P29/00 ,  A61P37/00 ,  A61P43/00 ,  A61K2035/115 ,  Y02A50/30

摘要： Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

公开(公告)号：US11654156B2

公开(公告)日：2023-05-23

申请号：US15844294

申请日：2017-12-15

申请人： ABBOTT LABORATORIES

发明人： Rachael Buck ,  Geralyn O. Duska-McEwen ,  Joseph P. Schaller

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/702 ,  A23L33/00 ,  A23L33/12 ,  A61K31/202 ,  A61K31/7016 ,  A61K45/06

CPC分类号： A61K31/702 ,  A23L33/12 ,  A23L33/40 ,  A61K31/202 ,  A61K31/7016 ,  A61K45/06 ,  A23V2002/00 ,  A23V2200/3202 ,  A23V2200/324 ,  A23V2250/1882 ,  A23V2250/28 ,  A61K2300/00 ,  A61K31/702 ,  A61K2300/00 ,  A61K31/7016 ,  A61K2300/00 ,  A61K31/202 ,  A61K2300/00 ,  A23V2002/00 ,  A23V2200/3202 ,  A23V2200/324 ,  A23V2250/1882 ,  A23V2250/28

摘要： Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

公开(公告)号：US11643431B2

公开(公告)日：2023-05-09

申请号：US17341694

申请日：2021-06-08

申请人： Aihol Corporation

发明人： Hua-Yang Lin

IPC分类号： A61K31/7016 ,  A61K31/728 ,  C07H19/056 ,  A61P11/00

CPC分类号： C07H19/056 ,  A61K31/7016 ,  A61K31/728 ,  A61P11/00

摘要： Disclosed herein is the use of a hyaluronan conjugate for treating pulmonary inflammation, including acute and chronic pulmonary inflammation. Also disclosed herein is the use of a hyaluronan conjugate for treating virus infection. The hyaluronan conjugate is a hyaluronic acid (HA)-nimesulide conjugate.